Both Sarclisa (isatuximab-irfc) and Darzalex Faspro (daratumumab hyaluronidase-fihj) are monoclonal antibodies used to treat multiple myeloma, and both have subcutaneous (under-the-skin) options available. Here's how they compare:
How They Work
- Both target the CD38 protein found in high amounts on myeloma cells
- Both Show Full Answer
Both Sarclisa (isatuximab-irfc) and Darzalex Faspro (daratumumab hyaluronidase-fihj) are monoclonal antibodies used to treat multiple myeloma, and both have subcutaneous (under-the-skin) options available. Here's how they compare:
How They Work
- Both target the CD38 protein found in high amounts on myeloma cells
- Both help the immune system recognize and destroy myeloma cells
- Neither is used alone — both are combined with other myeloma treatments
Subcutaneous Delivery
- Darzalex Faspro has been available as a subcutaneous injection since 2020
- Sarclisa Escena is the newer subcutaneous version of Sarclisa, recently FDA-approved
- Sarclisa Escena can be delivered via a hands-free on-body injector device (CirCLIQ), which is unique to it
Administration Time
- Sarclisa Escena takes roughly 6 minutes by manual injection or up to 20–60 minutes via the on-body device
- Both are significantly faster than their IV counterparts, which can take over 3 hours Common Side Effects (Both Drugs)
- Fatigue
- Low blood cell counts (platelets, white blood cells, hemoglobin)
- Increased infection risk
- Nausea or digestive issues
Sarclisa Escena-Specific Side Effects
- Injection-site reactions (redness, swelling, pain)
- Peripheral neuropathy (numbness or tingling)
- Trouble sleeping
- Rash
Both drugs may interfere with certain myeloma monitoring tests, so it's important your healthcare team is aware of which one you're taking.
The best choice between the two really depends on your treatment history, overall health, and personal preferences. It's worth having a detailed conversation with your care team about which option fits best into your treatment plan.
August 3
Join
Your Privacy Choices
